TALi Product Clinical & International Update & 4C
Filed with ASX · · 10 pages · English
TALi Digital Ltd (ASX: TD1, “TALi”or“the Company”), a leading global digital health business is pleased to provide the following quarterly activities report, together with its Appendix 4C for the quarter ended 31 December 2021 (Q2 FY2022). COMMERCIALISATION AND OPERATIONS UPDATE US Market–Akili Partnership TALi executed a Strategic Licensing Agreement with Akili, a global peer in the digital thera
Story so far
Earlier from TALi Digital
- Notification regarding unquoted securities - TD1
- TALi US License, Indian activities & Appendix 4C
- $500,000 Non-dilutive finance with victorian government
- Akili licenses TALi technology platform
- Appendix 4C - quarterly
Later from TALi Digital
- Half Yearly Report and Accounts
- Voluntary Suspension
- TALi Capital Raising
- Reinstatement to Official Quotation
- TALi Capital Raising Update
Follow TALi Digital into a list and get an email when it puts out news.
Follow TALi Digital